Compare Cronos Group Inc (CRON) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cronos Group Inc vs Sana Biotechnology Inc — how do they compare? Cronos Group Inc trades at $3.13 (market cap $1.14B), while Sana Biotechnology Inc trades at $3.73 (market cap $1.13B). The key difference: Cronos Group Inc and Sana Biotechnology Inc are close in size by market cap, and Cronos Group Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| CRON | SANA | |
|---|---|---|
Market Cap | $1.14B | $1.13B |
Sector | Health | Health |
52-Week High | $3.27 | $5.92 |
52-Week Low | $2.30 | $2.68 |
Enterprise Value | $341.13M | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cronos Group (CRON) trades at $3.125, up 4.17% today. The stock shows a bullish technical signal with strong moving average support. Recent Q2 2026 earnings beat expectations with $0.09 EPS versus $0.01 expected, driven by 58% YoY revenue growth. However, the company posted a net loss of $9.45M in 2025, though margins are improving from prior years.
Outlook is mixed; strong international expansion and product launches support growth, but negative cash flow and intense competition pose risks. Analyst consensus is cautious with 60% hold ratings. The stock offers growth potential but requires monitoring of profitability and cash management.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cronos Group Inc
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
